For more on David Nierengarten’s comments: We got an inside look at how the biotech Spark used mazes to develop a first-of-its-kind treatment for eye disease on the way to selling itself for $4.8 billion
David Nierengarten: Other Companies Have Similarly Sought to Target Eye Diseases but They Have Encountered More Challenges Then Expected.
